Wet AMD Drug Secures First FDA-Approved Bevacizumab Status

1. Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. 
2. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
3. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

The U.S. retina care market continues to draw attention from life sciences investors as new treatments address wet age-related macular degeneration, a leading cause of vision loss in older adults. Outlook Therapeutics Inc. (OTLK:NASDAQ) now stands at the center of this opportunity after securing regulatory clearance for its lead candidate.

Market Opportunity in Retina Care

Wet age-related macular degeneration damages central vision through abnormal blood vessel growth under the retina. Early detection and treatment remain critical, as noted by sources such as the Mayo Clinic. The condition affects millions in developed markets, creating sustained demand for anti-VEGF therapies that slow disease progression.

Why Outlook Therapeutics Stands Out

Outlook Therapeutics has received FDA approval for LYTENAVA to treat wet age-related macular degeneration (AMD). LYTENAVA is the first FDA-approved ophthalmic bevacizumab, offering an approved alternative to commonly used compounded versions. This milestone differentiates the company by delivering a purpose-built formulation designed specifically for intravitreal use rather than relying on repackaged intravenous products.

Key Investor Takeaways

• Outlook Therapeutics has received FDA approval for LYTENAVA to treat wet age-related macular degeneration (AMD).
• LYTENAVA is the first FDA-approved ophthalmic bevacizumab, offering an approved alternative to commonly used compounded versions.
• Outlook Therapeutics plans to launch LYTENAVA in the U.S. by the end of 2026 and target its estimated US$8.5 billion U.S. market.
• LYTENAVA is expected to receive up to 12 years of U.S. market exclusivity under the Biologics Price Competition and Innovation Act (BPCIA).
• Analysts raised price targets following the approval, reflecting updated probabilities of success.
• The company maintains a modest market capitalization with a shareholder base dominated by retail investors.

Unique Formulation and Regulatory Advantage

Outlook announced on July 24, 2026, that LYTENAVA has received U.S. Food and Drug Administration (FDA) approval. This designation establishes LYTENAVA as not only the first but the only FDA-approved ophthalmic bevacizumab treatment in the United States. This approval is also expected to lead to 12 years of Reference Product Exclusivity under the BPCIA. According to the release, "Outlook Therapeutics believes this FDA approval establishes a new benchmark for ophthalmic bevacizumab and positions LYTENAVA to become the new FDA-approved standard for bevacizumab therapy in patients with wet AMD. Bevacizumab already accounts for the majority of first-line anti-VEGF treatment in wet AMD, underscoring its important role in retina care."

Industry Timing and Broader Trends

Global medicine use is projected to grow substantially, with total drug usage expected to surpass four trillion doses daily by 2030, according to Iqvia, which discussed the global pharma market projection for 2026. In parallel,  a March 26, 2026, article for Fierce Biotech by Nick Paul Taylor wrote that pharma funding had fallen from 2024 but noted that, "2025 was still the third-best year of the past decade. Similarly, overall funding was well above the pre-pandemic norm and only topped by 2020, 2021, and 2024." BCG talked about trends biopharma companies need to be aware of in 2026 in order to stay competitive, saying, "Near term, companies need to continue to innovate to decrease the complexity and cost of these therapies, and governments can find ways to incentivize and pay for them."

Analyst Views and Valuation Update

After the release, on July 27, 2026, Douglas Tsao of H.C. Wainwright & Co. gave Outlook a "Neutral" rating but noted the new price target of US$1.60 due to the drug's approval. Tsao argued that ". . . approval represents a significant milestone, focus now turns to commercial opportunity in an evolving landscape." Tsao continued: "With the approval, we raise our price target to US$1.60, from our prior US$0.50 since we raised our POS for approval to 100%." Chen Lin of What is Chen Buying? What is Chen Selling? weighed in on the company's news on July 28, 2026, writing: "OTLK received FDA approval, after the FDA rejected it seven months ago! Its stock is down from "selling on the news" but appreciated greatly from 20c."

Launch Plans and Commercial Path

According to the company's press release, Outlook expects to launch LYTENAVA in the U.S. by the end of 2026 and will continue to expand the drug's reach from there. Outlook Therapeutics Inc. is a biopharma company focused on ophthalmic treatments for wet AMD, providing medication in Germany, Austria, and the U.K.

Share Structure and Ownership Profile

Outlook Therapeutics Inc. has a market cap of US$169.05 million, with 187.00 million shares outstanding. The company's 52-week range is US$0.16-US$3.39. ¹Institutions own 6% of shares, while Strategic Investors own 14.56%. Management & Insiders own 0.36%, and the remaining 79.08% of shares are held by Retail.

Common Questions from Investors

Q: What is wet age-related macular degeneration (wet AMD)?

A: Wet age-related macular degeneration (wet AMD) is an eye disease that damages the central part of the retina, causing blurred or distorted central vision. It happens when abnormal blood vessels grow under the retina and leak fluid or blood. Without treatment, the condition can lead to permanent vision loss.

Q: What is an FDA-approved treatment, and why does it matter?

A: An FDA-approved treatment has been reviewed by the U.S. Food and Drug Administration and found to meet standards for safety, effectiveness, and manufacturing quality. Approval gives physicians and patients confidence that the medicine has undergone rigorous testing before reaching the market.

Q: What is market exclusivity?

A: Market exclusivity is a period during which competing companies generally cannot market the same biologic medicine for the same use. This protection gives the original developer time to sell its product without direct competition, helping it recover the costs of research and development.

Q: Why do investors pay attention to FDA approvals?

A: FDA approval is often one of the biggest milestones for a biotech company. It allows the company to begin selling its treatment, generate revenue, and potentially expand into new markets, making approval a key event that can significantly affect a company's future.

Retail investors evaluating Outlook Therapeutics should weigh the approved product against execution risks around the planned 2026 launch and ongoing commercialization needs in a competitive retina market.